


CCP antibodies (cyclic citrullinated peptide) An early, specific marker for rheumatoid arthritis (RA)

Clinical rationale

- Early detection and intervention are essential for joint preservation and improved quality of life¹
- CCP antibodies appear up to 10 years before the clinical diagnosis of RA²
- CCP antibodies demonstrate greater specificity than RF while maintaining or increasing sensitivity^{3,4}
- CCP antibody results help physicians decide when aggressive therapy with biologicals is needed

Value of early diagnosis with CCP antibody testing⁵



Adapted from Klinkhoff.

“Irreversible joint erosion may occur early in the disease course in patients with rheumatoid arthritis (RA). . . . Therefore, it is important to diagnose RA correctly and fast.”¹

— Vander Cruyssen B, et al

EliA™: Results make the difference

CCP antibodies

- The first fully automated, licensed, and patented anti-CCP clinical marker in the US
- Unparalleled technical performance
 - Low variances and high reproducibility for consistent results
 - High lot-to-lot consistency using validated production procedures
- Excellent specificity and sensitivity

“...not all commercially available methods for the detection of [CCP antibodies] have the same degree of diagnostic accuracy, and... careful selection is needed to obtain reliable results.”⁶

— Bizzaro N, et al

Performance characteristics for early diagnosis⁶

Assay	Sensitivity at 98% specificity
EliA CCP antibodies	74%
Assay 1	64%
Assay 2	67%
Assay 3	67%
Rheumatoid factor (RF)	17%

Results from a comparative evaluation of second- and third-generation ELISA methods for the detection of antibodies to citrullinated proteins. Sensitivity and specificity of select kits are shown, along with those of RF, at cut-off levels provided by the manufacturers. Adapted from Bizzaro N, et al.

EliA: Automation makes it easy and economical

- Using the proven ImmunoCAP® 100€ and ImmunoCAP 250 *automated* laboratory systems
- Moderately complex
- High efficiency for reduced labor costs and hands-on time
 - Discrete single-well testing
 - One calibration curve per isotype stored for 28 days
 - IgA, IgE, IgG, IgM
- Onboard dilutions

References

1. Vander Cruyssen B, Nogueira L, Van Praet J, et al. Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. *Ann Rheum Dis*. 2008;67:542-546. 2. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. *Arthritis Rheum*. 2004;50(2):380-386. 3. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. *Rheumatology (Oxford)*. 2002;41(7):809-814. 4. Gilburd B, Praprotnik S, Showman O, Shoenfeld Y. Clinical diagnostic value of EliA™ fluorezyme-immunoassay for anti-cyclic citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis. Paper presented at: 4th International Congress on Autoimmunity; November 2004; Budapest, Hungary. 5. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. *Drugs*. 2004;64(12):1267-1283. 6. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. *Clin Chem*. 2007;53:1527-1533.

www.phadia.us

ImmunoCAP is a US registered trademark and EliA is a US trademark of Phadia AB

©2008 Phadia US Inc., a subsidiary of Phadia AB

Phadia

Phadia US Inc
4169 Commercial Avenue
Portage, MI 49002
800.346.4364

08018.01